Jiangsu Hengrui nears finish line with Apatinib for advanced gastric cancer
SHANGHAI – Jiangsu Hengrui Medicine Co. Ltd. released positive phase III data for apatinib at American Society of Clinical Oncology (ASCO) meeting last week and is now waiting for the good word from the CFDA for marketing approval in China. Apatinib, a molecular targeted therapy for the treatment of advanced gastric cancer has been shown to be associated with improved survival in patients with prior failure to second line chemotherapy.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter